Induction of apoptosis by gene transfer of human TRAIL mediated by arginine-rich intracellular delivery peptides

Anticancer Research

Volumn 30, Issue 6, 2010, Pages 2193-2202

  Li, Jheng Fong ^a   Huang, Yuliana ^a   Chen, Rong Long ^b   Lee, Han Jung ^a  

^a NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^b Lioying Chi Mei Hospital   (Taiwan)

Author keywords

Antitumor; Apoptosis; Cell penetrating peptide; Gene therapy; Protein transduction domain; Tumor necrosis factor related apoptosis inducing ligand

Indexed keywords

ARGININE RICH INTRACELLULAR DELIVERY PEPTIDE; CELL PENETRATING PEPTIDE; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN KAPPA CHAIN; PLASMID VECTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL BASED GENE THERAPY; CELL CYCLE S PHASE; CELL VIABILITY; CLINICAL EVALUATION; CYTOTOXICITY TEST; DRUG FORMULATION; DRUG MECHANISM; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LUNG CARCINOMA; NICK END LABELING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSIENT TRANSFECTION; WESTERN BLOTTING;

APOPTOSIS; ARGININE; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; IN SITU NICK-END LABELING; NEOPLASMS; PEPTIDES; PLASMIDS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77955081861     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Falschlehner C, Schaefer U and Walczak H: Following TRAIL'S path in the immune system. Immunol 127: 145-154, 2009.
2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA and Goodwin RG: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 5: 673-682, 1995.
3. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
4. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
5. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
6. Newsom-Davis T, Prieske S and Walczak H: Is TRAIL the holy grail of cancer therapy? Apoptosis 14: 607-623, 2009.
7. Wu GS: TRAIL as a target in anti-cancer therapy. Cancer Lett 285: 1-5, 2009.
8. Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S, Marini FC and Fang B: Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter. Clin Cancer Res 10: 3535-3541, 2004.
9. Jeong M, Kwon YS, Park SH, Kim CY, Jeun SS, Song KW, Ko Y, Robbins PD, Billiar TR, Kim BM and Soel DW: Possible novel therapy for malignant gliomas with secretable trimeric TRAIL. PLoS One 4: e4545, 2009.
10. Kock N, Kasmieh R, Weissleder R and Shah K: Tumor therapy mediated by lentivial expression of shBcl-2 and S-TRAIL. Neoplasia 9: 435-442, 2007.
11. Yoo J, Choi S, Hwang KS, Cho WK, Jung CR, Kwon ST and Im DS: Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor tumor model. J Gene Med 8: 163-174, 2006.
12. Zhang Y, Ma CH, Liu H, Zhang XM and Sun WS: pVAX1 plasmid vector-mediated gene transfer of soluble TRAIL suppresses human hepatocellular carcinoma growth in nude mice. Acta Biochim Pol 54: 307-313, 2007.
13. Shen J, Wu Y, Shi L, Liu J, Liu S, Guan Z and Yin Z: Construction and characterization of two versions of bifunctional EGFP-sTRAIL fusion proteins. Appl Microbiol Biotechnol 76: 141-149, 2007. (Pubitemid 47194667)
14. Schwarze SR, Ho A, Vocero-Akbani A and Dowdy SF: In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285: 1569-1572, 1999.
15. Strauss E: Intraducing proteins into the body's cells. Science 285: 1466-1467, 1999.
16. El-Sayed A, Futaki S and Harashima H: Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J 11: 13-22, 2009.
17. Fonseca SB, Pereira MP and Kelley SO: Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61: 953-964, 2009.
18. Gump JM and Dowdy SF: TAT transduction: the molecular mechanism and therapeutic prospects. Trends Mol Med 13: 443-448, 2007.
19. Rapoport M and Lorberboum-Galski H: TAT-based drug delivery system - new directions in protein delivery for new hopes? Expert Opin Drug Deliv 6: 453-463, 2009.
20. Green M and Loewenstein PM: Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT trans-activator protein. Cell 55: 1179-1188, 1988. (Pubitemid 19020070)
21. Frankel AD and Pabo CO: Cellular uptake of the TAT protein from human immunodeficiency virus. Cell 55: 1189-1193, 1988.
22. Vives E, Brodin P and Lebleu B: A truncated HIV-1 TAT protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 272: 16010-16017, 1997.
23. Dietz GP and Bahr M: Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol Cell Neurosci 27: 85-131, 2004.
24. Chang M, Chou JC, Chen CP, Liu BR and Lee HJ: Noncovalent protein transduction in plant cells by macropinocytosis. New Phytol 174: 46-56, 2007.
25. Hou YW, Chan MH, Hsu HR, Liu BR, Chen CP, Chen HH and Lee HJ: Transdermal delivery of proteins mediated by non-covalently associated arginine-rich intracellular delivery peptides. Exp Dermatol 16: 999-1006, 2007.
26. Hu JW, Liu BR, Wu CY, Lu SW and Lee HJ: Protein transport in human cells mediated by covalently and noncovalently conjugated arginine-rich intracellular delivery peptides. Peptides 30: 1669-1678, 2009.
27. Liu BR, Chou JC and Lee HJ: Cell membrane diversity in noncovalent protein transduction. J Membr Biol 222: 1-15, 2008.
28. Wang YH, Chen CP, Chan MH, Chang M, Hou YW, Chen HH, Hsu HR, Liu K and Lee HJ: Arginine-rich intracellular delivery peptides noncovalently transport protein into living cells. Biochem Biophy Res Commun 346: 758-767, 2006.
29. Wang YH, Hou YW and Lee HJ: An intracellular delivery method for siRNA by an arginine-rich peptide. J Biochem Biophys Methods 70: 579-586, 2007. (Pubitemid 46669686)
30. Chen CP, Chou JC, Liu BR, Chang M and Lee HJ: Transfection and expression of plasmid DNA in plant cells by an arginine-rich intracellular delivery peptide without protoplast preparation. FEBS Lett 581: 1891-1897, 2007.
31. Chang M, Chou JC and Lee HJ: Cellular internalization of fluorescent proteins via arginine-rich intracellular delivery peptide in plant cells. Plant Cell Physiol 46: 482-488, 2005.
32. Lin YL, Wang YH and Lee HJ: Transcriptional regulation of the human TR2 orphan receptor gene by nuclear factor 1-A. Biochem Biophy Res Commun 350: 430-436, 2006.
33. Lee HJ, Young WJ, Shih CCY and Chang C: Suppression of the human erythropoietin gene expression by the human TR2 orphan receptor, a member of the steroid receptor superfamily. J Biol Chem 271: 10405-10412, 1996.
34. Wang CP, Lee YF, Chang C and Lee HJ: Transactivation of the proximal promoter of human oxytocin gene by TR4 orphan receptor. Biochem Biophy Res Commun 351: 204-208, 2006.
35. Chang M, Hsu HY and Lee HJ: Dye-free protein molecular weight markers. Electrophoresis 26: 3062-3068, 2005.
36. Torchilin VP, Levchenko TS, Rammohan R, Volodina N, Papahadjopoulos- Sternberg B and D'Souza GG: Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci USA 100: 1972-1977, 2003.
37. Dowdy SF and Snyder EL: Recent advances in the use of protein transduction domains for the delivery of peptides, proteins and nucleic acids in vivo. Expert Opin Drug Deliv 2: 43-51, 2005.
38. Kuciak M, Gabus C, Ivanyi-Nagy R, Semrad K, Storchak R, Chaloin O, Müller S, Mely Y and Darlix JL: The HIV-1 transcriptional activator TAT has potent nucleic acid chaperoning activities in vitro. Nucl Acids Res 36: 3389-3400, 2008.
39. Ziegler A and Seelig J: High affinity of the cell-penetrating peptide HIV-1 TAT-PTD for DNA. Biochemistry 46: 8138-8145, 2007.
40. Almasan A and Ashkenazi A: Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev 14: 337-348, 2003.
41. Bosque A, Aguilo JI, del Rey M, Paz-Artal E, Naval J and Anel A: Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes. J Leukoc Biol 84: 488-498, 2008.
42. Kastan MB and Bartek J: Cell-cycle checkpoints and cancer. Nature 432: 316-323, 2004.
43. Thorburn A: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J Thorac Oncol 2: 461-465, 2007. (Pubitemid 47171799)